title: Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in western Turkey.
abstract: BACKGROUND
  To investigate epidermal growth factor receptor (EGFR) gene mutations in patients with non- small cell lung cancer (NSCLC) and to analyze any relationship with clinicopathological features and prognosis.
  
  
  METHODS
  EGFR gene exons 18-21 in 48 specimens of paraffin-embedded tumor tissue from NSCLC patients were amplified by PCR, followed by direct sequencing and analysis of links to clinicopathological features and prognosis.
  
  
  RESULTS
  EGFR mutations were detected in 18 of 48 (42.6%) patients with NSCLC. There were 9 cases of mutations in exon 20, 7 in exon 19 and 2 in exon 21. Mutations were more frequently observed in women (5/7 pts, 71.4%) than in men (13/41 pts, 31.7%) (p=0.086) and in non-smokers (5/5 pts, 100%) than smokers (13/43 pts, 30.2%). There was negative correlation of EGFR mutations with smoking status (p=0.005). EGFR mutations were more frequently observed with adenocarcinoma histology (13/32 pts, 40.6%) than in other types (5/16 pts, 31.3%) (p=0.527). The patients with EGFR mutations had better survival than those with wild- type EGFR (p=0.08). There was no association of EGFR mutations with metastatic spread.
  
  
  CONCLUSIONS
  EGFR mutations in NSCLC were here demonstrated more frequently in females, non-smokers and adenocarcinoma histology in the western region of Turkey. Patients with EGFR mutations have a better prognosis.
authors.affiliation: Department of Medical Oncology, Dokuz Eylul University, Turkey. drolcun@hotmail.com
authors.forename: Olcun Umit
authors.initials: OU
authors.lastname: Unal
authors.forename: Ilhan
authors.initials: I
authors.lastname: Oztop
authors.forename: Gizem
authors.initials: G
authors.lastname: Calibasi
authors.forename: Yasemin
authors.initials: Y
authors.lastname: Baskin
authors.forename: Dogan
authors.initials: D
authors.lastname: Koca
authors.forename: Necla
authors.initials: N
authors.lastname: Demir
authors.forename: Tulay
authors.initials: T
authors.lastname: Akman
authors.forename: Hulya
authors.initials: H
authors.lastname: Ellidokuz
authors.forename: Ahmet Ugur
authors.initials: AU
authors.lastname: Yilmaz
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018287:Carcinoma, Large Cell / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D014421:Turkey
chemical_list: C512478:EGFR protein, human; D066246:ErbB Receptors